Trials / Completed
CompletedNCT06286254
Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection
Non-interventional Prospective Study of Safety and Efficacy of the Drug Cycloferone® (NTFF "POLYSAN" Ltd., Russia) in Patients with Acute Respiratory Viral Infection At the Outpatient Stage
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 742 (actual)
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study will collect the information on clinical effects and safety of the basic therapy of acute respiratory viral infection (ARVI) + Cycloferone® and basic therapy of ARVI1 + Arbidol® in real-life clinical settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cycloferone | Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8. |
Timeline
- Start date
- 2023-09-20
- Primary completion
- 2024-04-20
- Completion
- 2024-09-30
- First posted
- 2024-02-29
- Last updated
- 2024-12-16
Locations
13 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT06286254. Inclusion in this directory is not an endorsement.